FDA queries drug-coated stent trial protocols
This article was originally published in Clinica
Executive Summary
Biocompatibles International and Boston Scientific are anticipating slight delays in starting their respective drug-coated stent trials in the US, after the US FDA requested further information in response to the firms' investigational device exemption (IDE) submissions.